secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001213900-24-013804
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phoenix Biotech Acquisition amends CERo merger earnout; adds 1.875M shares with closing and IND milestones
--------------------------------------------------------------------------------

- Amendment creates 875,000 earnout shares fully vested at closing, offsetting sponsor forfeiture.
- Adds 1,000,000 earnout shares vesting upon FDA IND application submission (regulatory milestone).
- Existing price-based earnout targets: $12.50 (500K shares) and $15.00 (500K shares) VWAP thresholds.
- Total Company Stockholders Earn-Out Consideration now 3,075,000 shares per new allocation schedule.
- Technical changes to timing and process for earnout issuance, plus HSR filing provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024013804/0001213900-24-013804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390024013804/ea193537-8k425_phoenix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-013804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer